Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and Glatiramer Acetate

Publisher： Karger

E-ISSN： 1421-9913|65|4|231-232

ISSN： 0014-3022

Source： European Neurology, Vol.65, Iss.4, 2011-03, pp. : 231-232

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice

By  

European Neurology, Vol. 76, Iss. 1-2, 2016-07 ,pp. : 40-47

Karger

Access to resources Recommend Favorite

The Treatment of Multiple Sclerosis with Beta-Interferon

By  

Neuroepidemiology, Vol. 31, Iss. 3, 2008-08 ,pp. : 157-158

Karger

Access to resources Recommend Favorite

Description of the Characteristics of Multiple Sclerosis Patients in the Region of Valencia (Spain) Who Requested Treatment with Disease-Modifying Drugs during the 2005-2014 Decade

By  

European Neurology, Vol. 75, Iss. 5-6, 2016-06 ,pp. : 274-281

Karger

Access to resources Recommend Favorite

Coping Strategy and Anxiety Evolution in Multiple Sclerosis Patients Initiating Interferon-Beta Treatment

By  

European Neurology, Vol. 62, Iss. 2, 2009-06 ,pp. : 79-85

Karger

Access to resources Recommend Favorite

Effect of Interferon-beta-1b on Cognitive Functions in Multiple Sclerosis

By  

European Neurology, Vol. 47, Iss. 1, 2002-01 ,pp. : 11-14

Karger

Access to resources Recommend Favorite